Amplio Pharma now planning a phase 2a study after NovoBioJect raised intracellular active methotrexate levels by 38%.
|Videos|November 25, 2020
Treatment Choices: Rheumatoid Arthritis Case Study
Advertisement
Dr. Christopher Parker, a rheumatologist with The Austin Diagnostic Clinic in Austin, Texas, reviews the following case of a women with rheumatoid arthritis interested in receiving a JAK inhibitor.
Case: Rheumatoid arthritis (RA) active disease in an adult female patient with inadequate response to methotrexate.
Initial Presentation and Treatment:
- A 53-year-old woman was diagnosed with RA approximately 7 years ago.
- Confirmed by anti-cyclic citrullinated peptide testing
- Following diagnosis, she received methotrexate at 10 mg/week, which was escalated to 25 mg/week over time
- She received modified-release prednisone 5 mg/day in the evenings
- She has not received a biological DMARD
Subsequent Treatment and Follow-up:
- On a scale of 0 to 100 mm by visual analog scale, PhGA is 64, the PtGA is 62, and pain is 63.
- DAS28-CRP is 5.8, DAS28-ESR is 6.5, and hs-CRP is 20 mg/L
- Lab measures are normal for neutrophil, lymphocyte, hemoglobin, and liver enzyme counts
- The patient went on to receive upadacitinib at 15 mg/day.
Advertisement
Related to this article
The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement